Epidemiological, haematological-biochemical, and molecular investigations of bovine theileriosis with therapeutic evaluation of buparvaquone with silymarin in Dakahlia and Damietta governorates, Egypt.

Abstract

HISTORY: Bovine theileriosis, caused by Theileria annulata and transmitted by Hyalomma ticks, is a major constraint on cattle health and productivity in Egypt, leading to economic losses. AIMS: This study determines the molecular prevalence of T. annulata in cattle from Dakahlia and Damietta, evaluates associated risk factors, and assesses hematological and biochemical changes in infected animals. The therapeutic efficacy of buparvaquone (BVQ) alone or combined with silymarin (SI) was also investigated. METHODS: Blood samples were collected from 149 cattle; infection was confirmed by Tams1 gene PCR and phylogenetic analysis. Risk factors were statistically assessed. Twenty clinically infected cows were divided into two groups (n&#x2009;=&#x2009;10); one received BVQ, while the other received BVQ plus SI. Hematological, biochemical, acute-phase proteins, and beta-hydroxybutyrate were measured before and two weeks after treatment. RESULTS: PCR analysis confirmed Theileria annulata infection in 32.9% of cattle, with our isolates (PQ137836 and PQ137837) showing 99.7-100% sequence similarity to both local and global strains. Infection was highest in tick-infested cattle (69.84%, OR&#x2009;=&#x2009;5.62), pregnant cows (50%, OR&#x2009;=&#x2009;6.7), and animals not treated with ectoparasiticides (91.8%, OR&#x2009;=&#x2009;8.6). Combination therapy significantly reduced parasitemia (3.76% to 0.18%, p&#x2009;<&#x2009;0.001), improved hematological, liver, and metabolic indices, decreased APPs, and increased paraoxonase-1 activity, compared to BVQ alone. IN CONCLUSION: Bovine theileriosis is highly prevalent in Dakahlia and Damietta, particularly in middle-aged, pregnant, and tick-infested cattle during the summer. Molecular analysis confirmed Theileria annulate infection. Combination therapy with BVQ and SI proved more effective than BVQ monotherapy.